VERRICA PHARMACEUTICALS INC
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Find out what a historical investment in VERRICA PHARMACEUTICALS INC would be worth today using our VRCA stock calculator.
$74.60M
-
0.00%
1.03K
$0.90
$0.77
$0.00
$8.98
$0.38
Ready to start your investing journey with Stake?
Open an accountVRCA FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in VRCA
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in VRCA
on Stake
Buy VRCA from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of VRCA from only US$10 with fractional shares
